Spring direct naar de hoofdnavigatie of de inhoud
‘To explore, together with a client, how the best IP protection can be obtained is for me the logical next step after an invention has been made.’
Frits Michiels

Frits Michiels

  • Life Sciences
  • European and Dutch Patent Attorney
  • Partner

Frits Michiels has had an extensive scientific career in both knowledge institutes and biotech companies. From 2004, he was employed as IP manager at Galapagos Genomics BV and subsequently also at other Dutch biotech startups, such as Agendia and Merus. He has worked for V.O. since 2006.

Continue reading

He is specialized in biochemistry, molecular biology, cell biology, diagnostics, signal transduction, and medical biotechnology. His clients are primarily knowledge institutes and start ups. He is involved in patent prosecution and strategic advice.

Working experience

  • Patent Attorney, V.O. (2006-present)
  • Merus (2006)
  • Galapagos Genomics (1999-2005)
  • Senior Scientist at the Netherlands Cancer Institute (1994-1998)
  • Post-Doc, Amsterdam Medical Center (1991-1993)
  • PhD research at Max Planck Institute for Biochemistry, Munich (1985-1990)

Education

  • PhD in Genetics, Radboud University Nijmegen (1990)
  • MSc in Microbiology, Radboud University Nijmegen (1984)

Publications

  • Michiels, GAM Damages extended to after termination of a tort. MIP Vol 205: 94-95 (2011)
  • JP ten Klooster, EE Evers, L Janssen, LM Machesky, F Michiels, P Hordijk and JG Collard. Biochem J. 397, 39–45 (2006)
  • GJ Arts, E Langemeijer, R Tissingh, L Ma, H Pavliska, K Dokic, R Dooijes, E Mesić, R Clasen, F Michiels, J van der Schueren, M Lambrecht, S Herman, R Brys, K Thys, M Hoffmann, P Tomme, H van Es. Genome Res 13, 2325-32 (2003)
  • A Malliri, RA van der Kammen, K Clark, M van der Valk, F Michiels & JG Collard. Nature 417, 867-871 (2002)
  • F Michiels et al. Nature Biotech 20, 1154-1157 (2002)
  • R Engers, E Springer, F Michiels, JG Collard, HE Gabbert. J Biol Chem 276, 41889-97 (2001)
  • WO2002057463 Swap/counter selection; a rapid cloning
  • WO2002070744 Adenoviral library assay for E2F regulatory genes and methods and compositions for screening compounds method
  • WO2005124342 Methods and means for treatment of osteoarthritis

Languages

  • English
  • Dutch
  • German

Also see these experts

Mark Einerhand

Mark Einerhand

  • European and Dutch Patent Attorney
  • Partner
Hajo Kraak

Hajo Kraak

  • European and Dutch Patent Attorney
  • Partner
More experts

News

Phasing out of Australian innovation patent

In Australia, there is the possibility to apply for a so-called innovation patent, which is in many ways similar to the utility model.Continue reading

Video conferences not in violation of European Patent Convention

On July 16, the Enlarged Board of Appeal (EBoA) of the European Patent Office (EPO) gave first indication of the content of the decision in the case G 1/21 concerning video conferencing.Continue reading

Column – ‘Emerging from the crisis in an innovative way’

It is unbelievable, but for almost a year the world has been in an unreal crisis. For some companies, there is economic prosperity and the crisis passes silently and for others, this crisis has caused a lot of economic pain.Continue reading

Events

Scale up digital – grow your business

Amsterdam Science Park, Science Park, Amsterdam

Growth is not easy to achieve. Especially not on your own, because you are busy with your daily business. Continue reading

Knowledge for Growth 2021

Gent ICC, Familie van Rysselberghedreef, Ghent, België

Join us on 27, 28 and 29 September together with 1000+high-level life scieces actors from 500+ companies and organisations. Continue reading

Dutch Lifes Sciences Conference 2021

CORPUS Congress Centre, Willem Einthovenstraat, Oegstgeest, Netherlands

The foremost life sciences business network event in the Netherlands. Continue reading